Je was op zoek naar: ppis (Engels - Maltees)

proton pump inhibitors (ppis)
inibituri tal-proton pump (ppis)

antacids and proton pump inhibitors (ppis)
antaċidi u inibituri tal-pompa tal-protoni (ppis)

no conclusive data on the pharmacodynamic interaction of clopidogrel and other ppis are available.
ebda data konklużiva dwar l-interazzjoni farmakodinamika ta' clopidogrel u ppis oħra huma disponibbli.

when given together with ppis, methotrexate levels have been reported to increase in some patients.
meta ngħata flimkien ma’ ppis, il-livelli ta’ methotrexate ġew irrapportati li żdiedu f’xi pazjenti.

the suitability of ppis needs to be assessed on a case by case basis before they can be considered appropriate.
kemm huma xierqa l-ipp-ijiet jeħtieġu li jiġu stmati fuq bażi ta' każ każ qabel ma jkunu jistgħu jitqies u bħala xierqa.

(ii) proton pump inhibitors (ppis) in the last 14 days?
(ii) xi inibituri tal-pompa tal- proton (ppis) fl-aħħar 14-il jum?

caution should be exercised when administering bosulif concomitantly with proton pump inhibitors (ppis).
għandha tintuża kawtela meta bosulif ikun amministrat flimkien ma’ inibituri tal-proton pump (ppis).

the recommendations for how ppis and h2-receptor antagonists are co-administered are based on physiological considerations.
ir-rakkomandazzjonijiet dwar kif il- ppis u l-antagonisti tar-riċettur h2 għandhom jingħataw flimkien huma bbażati fuq fatturi fiżjoloġiċi.

when comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking ppis versus mycophenolate mofetil patients not taking ppis, no significant differences were seen.
meta wieħed iqabbel ir-rati ta’ rifjut ta’ trapjant jew ir-rati ta’ telf ta’ trapjant bejn pazjenti fuq mycophenolate mofetil li jieħdu ppis versus pazjenti fuq mycophenolate mofetil li ma kienux qed jieħdu ppis, ma kienux osservati differenzi sinifikanti.

when comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking ppis vs. mycophenolate mofetil patients not taking ppis, no significant differences were seen.
meta wieħed iqabbel ir-rati ta’ rifjut ta’ trapjant jew ir-rati ta’ telf ta’ trapjant bejn pazjenti fuq mycophenolate mofetil li jieħdu ppis vs pazjenti fuq mycophenolate mofetil li ma kienux qed jieħdu ppis, ma kienux osservati differenzi sinifikanti.

20 erlotinib with omeprazole, a proton pump inhibitor (ppi), decreased the erlotinib exposure [auc] and maximum concentration [cmax] by 46% and 61%, respectively.
l- għotja flimkien ta ’ erlotinib ma ’ omeprazole, inibitur tal- pompi tal- protoni (ppi), naqqsu l- espożizzjoni għal erlotinib [auc] u l- konċentrazzjoni massima [cmax] b ’ 46% u 61%, rispettivament.